SCHEMBL5887545

SCHEMBL5887545

Cc1nc(N2CCC(C(=O)c3ccc(F)cc3)CC2)nc2c1ccc(=O)n2-c1ccc(C(N)=O)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 7/20 0.40
LMNA P02545 1/20 0.40
STAT3 P40763 1/20 0.38
KDM4E B2RXH2 2/20 0.38
POLB P06746 1/20 0.38
GAA P10253 1/20 0.38
MEN1 O00255 1/20 0.38
CYP3A4 P08684 1/20 0.38
HTR1A P08908 1/20 0.38
CYP2D6 P10635 1/20 0.38
MAPT P10636 1/20 0.38
PKM P14618 1/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38
HTR2C P28335 1/20 0.38
THPO P40225 1/20 0.38
PMP22 Q01453 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HTR2A P28223 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5887520 0.89 MEN1 (0.44) LMNAKDM4EPOLBGAAMEN1
SCHEMBL5887004 0.88 CCNE1 (0.47) POLB
SCHEMBL5887117 0.84 SMN1; SMN2 (0.49) KDM4EPOLBSMN1; SMN2
SCHEMBL5887369 0.83 KDM4E (0.41) KDM4EMEN1KMT2A
SCHEMBL5886731 0.82 KDM4E (0.41) LMNAKDM4EPOLBMEN1MAPT
SCHEMBL5887260 0.82 KMT2A (0.42) HSD11B1LMNAKDM4EPOLBMEN1
SCHEMBL5886975 0.82 MAPT (0.47) LMNAPOLBGAAMEN1MAPT
SCHEMBL5887184 0.82 CHEK1 (0.46) KDM4EMEN1CYP3A4CYP2D6HPGD
SCHEMBL5887547 0.81 PRKAB2 (0.41) LMNAKDM4EPOLBMEN1KMT2A
SCHEMBL5886930 0.80 MEN1 (0.44) LMNAKDM4EMEN1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US claimed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors TERT, TERF2, TERF2IP HSD11B1 4244/4885LMNA 711/4885STAT3 2948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.